title: Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor.
abstract: PG9 and PG16 are two quaternary-structure-specific broadly neutralizing antibodies with unique HCDR3 subdomains. Previously, we showed that glycosylphosphatidylinositol (GPI)-anchored HCDR3 subdomains (GPI-HCDR3) can be targeted to lipid rafts of the plasma membrane, bind to the epitope recognized by HCDR3 of PG16, and neutralize diverse HIV-1 isolates. In this study, we further developed trimeric GPI-HCDR3s and demonstrated that trimeric GPI-HCDR3 (PG16) dramatically improves anti-HIV-1 neutralization, suggesting that a stoichiometry of recognition of 3 or 2 HCDR3 molecules (PG16) to 1 viral spike is possible.
authors.affiliation: Unit of Anti-Viral Immunity and Genetic Therapy, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China.
authors.forename: Lihong
authors.initials: L
authors.lastname: Liu
authors.forename: Weiming
authors.initials: W
authors.lastname: Wang
authors.forename: Lifei
authors.initials: L
authors.lastname: Yang
authors.forename: Huanhuan
authors.initials: H
authors.lastname: Ren
authors.forename: Jason T
authors.initials: JT
authors.lastname: Kimata
authors.forename: Paul
authors.initials: P
authors.lastname: Zhou
mesh_terms: D000911:Antibodies, Monoclonal / Q000235:genetics / Q000494:pharmacology; D057134:Antibodies, Neutralizing / Q000235:genetics / Q000494:pharmacology*; D017261:Glycosylphosphatidylinositols / Q000378:metabolism; D015483:HIV Antibodies / Q000235:genetics / Q000494:pharmacology*; D023581:HIV Fusion Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology*; D053586:Virus Internalization / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D017261:Glycosylphosphatidylinositols; D015483:HIV Antibodies; D023581:HIV Fusion Inhibitors